1,721,037 research outputs found
Incidence of community-acquired pneumonia caused by Chlamydia pneumoniae in Italian patients
No full textThe incidence of Chlamydia pneumoniae as a cause of community-acquired pneumonia was evaluated in a one-year prospective study in 108 patients with community-acquired pneumonia. The bacteriological diagnosis was based on culture of sputum or bronchial aspirate and examination of acute and convalescent phase sera for Mycoplasma pneumoniae, Legionella pneumophila and Chlamydia pneumoniae. A definitive microbiological diagnosis was obtained in 58 (54 %) patients. Chlamydia pneumoniae was the causative agent in 14 patients (13 %) on the basis of positive serological tests; in 10 of the 14 patients Chlamydia pneumoniae was also detected by means of an indirect immunofluorescence test using pharyngeal swab specimens. In conclusion, Chlamydia pneumoniae seems to be a common etiological agent of community-acquired pneumonia, as increasingly reported in the last six to seven years
Steps forward in LRTI and tuberculosis : update from the ERS Respiratory infections assembly
No full textLower respiratory tract infections (LRTIs) and tuberculosis are among the leading reasons for seeking medical care.
In the present report, the most recent advances in the fields of clinical research and basic science of LRTIs and tuberculosis are presented through analysis of some of the best abstracts presented at the 18th European Respiratory Society Annual Congress in Berlin.
The role of viruses in chronic obstructive pulmonary disease exacerbations and the importance of new biomarkers in the diagnosis of bacterial infections in LRTI are discussed.
New tools for the diagnosis of latent and active tuberculosis in special subgroups of patients (children, immunocompromised individuals, etc.), and the new epidemiological threat of multidrug-resistant and extensively drug-resistant tuberculosis cases is analysed
Chlamydia pneumoniae and Mycoplasma pneumoniae
No full textMycoplasma pneumoniae infection occurs worldwide and is the most common cause of community-acquired pneumonia (CAP) in 5- to 20-year-olds. The most reliable diagnostic test is the enzyme immunoassay, which allows immunoglobulin (Ig)G and IgM titration and presents 92% sensitivity and 95% specificity on paired samples. Potentially active drugs are tetracyclines, macrolides, ketolides, lincosamides, streptogamines, chloramphenicol, and fluoroquinolones. Chlamydia pneumoniae accounts for 6 to 20% of CAP cases, depending on several factors such as setting of the studied population, age group examined, and diagnostic methods used. The current gold standard for serological diagnosis of acute infection is microimmunofluorescence testing. Tetracyclines and erythromycin show good in vitro activity and so far have been the most commonly employed drugs in the treatment of C. pneumoniae infection. New macrolides, ketolides, and new fluoroquinolones are other potentially effective drugs
La tomografia elettrica come tecnica per la caratterizzazione idraulica dei mezzi porosi ed il monitoraggio dei processi transitori
No full textColonisation in Stable Patients with COPD: Results of an Italian Epidemiological Study (Prime Study)
No full textNoninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? : look at the bicarbonates
No full textHydro-Mechanical Coupling in Saturated and Unsaturated Soilsand its Consequences on the Electrical Behaviour
No full text
- …
